Asia-Pacific Venous Diseases Treatment Market – Industry Trends and forecast period of 2021 to 2030.
Asia-Pacific venous diseases treatment market Data Bridge Market Research analyzes that the Asia-Pacific Venous Diseases Treatment Market is expected to reach the value of USD 2,118.93 million by 2030, at a CAGR of 8.4% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
According to the World Journal of Surgery and Surgical Research, in 2021, the overall prevalence of chronic venous insufficiency was 45.6% in both men and women. Also, in 2021, a prevalence study conducted in primary healthcare centers in the Qassim region of Saudi Arabia showed that varicose veins in men and women were 61.1%. A new survey-based study with Doppler ultrasound in the Republic of Korea found that female nurses had a 16.18% lower incidence of varicose veins.
Rising Incidences of Asia-Pacific Venous Diseases
Asia-Pacific Venous diseases are conditions that damage veins in the body. Damaged blood vessel walls prevent the circulatory system from working, causing blood to pool and reflux (backward) when the muscles relax. This causes abnormally high pressure to build up in the veins. This buildup causes veins to tighten and twist, increased swelling, increased valve incompetence, slow blood flow, and possible blood clots. Finally, this condition can lead to various diseases known as Asia-Pacific Venous diseases.
There are many types of Asia-Pacific Venous diseases that can develop for different reasons. Some of the more common disorders are:
- Blood clots
- Chronic Asia-Pacific Venous insufficiency
- Deep vein thrombosis
- Phlebitis
- Varicose veins and spider veins
Patients with a history of deep vein thrombosis, varicose veins, or other Asia-Pacific Venous diseases are at increased risk of cardiovascular disease. A family history of these diseases also increases a patient's risk of CVD1. Untreated CVD can lead to chronic Asia-Pacific Venous insufficiency (CVI). Asia-Pacific Venous disorders are pretty common nowadays.
Request Access for Free Sample Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-venous-diseases-treatment-market
Segment Analysis:
The Asia-Pacific Venous diseases treatment market is segmented on the basis of product type, disease type, treatment type, end user and distribution channel.
On the basis of product type, the global Asia-Pacific Venous diseases treatment market is segmented into ablation devices, sclerotherapy injection, Asia-Pacific Venous stents, Asia-Pacific Venous closure products, medications and others.
In 2023, the sclerotherapy injection segment in product type segment is anticipated to dominate the Asia-Pacific Venous diseases treatment market
In 2023, the sclerotherapy injection segment is expected to dominate the global Asia-Pacific Venous diseases treatment market due to this associated with fewer side effects, and less scarring, easier to recover from, and less damaging to surrounding tissue, and it’s less expensive. The segment is expected reach the highest CAGR of 8.4% in the forecast period of 2023-2030.
On the basis of disease type, the global Asia-Pacific Venous diseases treatment market is segmented into deep vein thrombosis (DVT), chronic Asia-Pacific Venous insufficiency (CVI), pulmonary embolism, superficial thrombophlebitis, varicose veins and others. In 2023, the Varicose veins segment is expected to dominate the market with a 33.65% market share due to rapid changes in lifestyle leading to obesity and other factors.
On the basis of treatment type, the global Asia-Pacific Venous diseases treatment market is segmented into compression therapy, veno active medication, surgeries, scelrotherapy, angioplasty or stenting, vein ligation and stripping, vena cava filter, ambulatory phlebectomy, radiofrequency ablation therapy, laser treatment, compression therapy and other therapies. In 2023, the sclerotherapy segment is expected to dominate the market with a 21.53% market share due to need for early and proper diagnosis for the Asia-Pacific Venous disorders.
For instance,
In April 2020, Polyplus Transfection expanded its partnership with the Warburg Pincus and ArchiMed. Warburg Pincus is one of the equity firm focused on investment. ArchiMed is an equity healthcare specialist who will advance the development and sale of Polyplus' breakthrough solutions. Through this agreement, the company is expected to accelerate the production capacity of several of its major transfection products. This investment allowed the company to access resources form both the companies and to attain a lucrative growth.
The investments done by several companies allowed the development and introduction of new and innovative transfection instruments and reagent in the market. These innovative products have enhanced the transfection efficiency and boosted the manufacturer's credibility in the market. This thus signifies that the surging level of investment is acting as an opportunity for the global transfection reagent and equipment market growth.
Access Full Report: https://www.databridgemarketresearch.com/reports/Asia-Pacific-venous-diseases-treatment-market
Segments Covered
By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bio production and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).
Countries Covered
Geographically, the countries covered in the Asia-Pacific Venous diseases treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Belgium, Switzerland, Ireland, rest of Asia-Pacific in Asia-Pacific, China, India, Japan, South Korea, Thailand, Singapore, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific in the Asia-Pacific (APAC), Brazil, Argentina, rest of South America as part of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East and Africa as a part of Middle East and Africa (MEA).
Market Players Covered
Data Bridge Market Research recognizes the following companies as the major Asia-Pacific Venous diseases treatment market players in global Asia-Pacific Venous diseases treatment market are Abbott (U.S.), Imricor (U.S.), Baylis Medical Company, Inc. (Canada), Theraclion (France), Sonablate (U.S.), plusmedica.de (Germany), Boston Scientific Corporation (U.S.), Olympus Corporation (Japan), Smith + Nephew (U.K.), Cook (U.S.), SCITECH (Brazil), Carl Zeiss Meditec AG(Germany), Teleflex incorporated (U.S.), Alma Lasers (Israel), BD (U.S.), B.Braun SE (Germany) , Medtronic (Ireland), Stryker (U.S.), Koninklijke Philips N.V.(Netherlands), Varian Medical Systems (U.S.), Candela Corporation (U.S.), Terumo Corporation (Japan), Angiodynamics (U.S.), and Optimed Medizinische Instrumente GmbH (Germany).
COVID-19 Impact Analysis
The outbreak of COVID-19 largely impacted the healthcare industry. The Asia-Pacific Venous diseases treatment market was, however adversely affected by it. The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to emergence of various challenges such as the denied clinics, cancelled or postponed diagnosis and treatment, stifling business growth, suspensions of new developments and even increasing cases in COVID-19 medical care providers, further limiting the industry's expansion. As the admission of COVID-19 patients in hospitals increased, numerous vascular or Asia-Pacific Venous surgeries or treatments were cancelled or postponed to reserve hospital beds and patient care staff to COVID-19 patient care. The developing and implementing contingency plans is highly crucial for business operations and key imported raw materials.
On the brighter side, there has been a decline in COVID-19 patients worldwide, which will result in increased hospital services. Moreover, the restrictions and measures are likely to relax, which will help market to witness a slight increment, as the manufacturers are focusing on various developments and innovations, market trends, and other expansion strategies. Thus, Asia-Pacific Venous diseases treatment market will grow at an accelerated pace post COVID-19.
Get TOC of the Report: https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-venous-diseases-treatment-market
Asia-Pacific Venous Diseases Treatment Market
Chapter One: Introduction
Chapter Two: Market Segmentation
Chapter Three: Market Overview
Chapter Four: Executive Summary
Chapter Five: Premium Insights
Chapter Six: Asia-Pacific Venous Diseases Treatment Market
Browse Treading Reports @
- Asia-Pacific Compound Management Market
- Asia-Pacific Compound Management market
- Middle East and Africa Compound Management market
- North America Compound Management market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email : Sopan.gedam@databridgemarketresearch.com
